CN112791091B - 王不留行黄酮苷在改善肠道屏障功能中的应用 - Google Patents
王不留行黄酮苷在改善肠道屏障功能中的应用 Download PDFInfo
- Publication number
- CN112791091B CN112791091B CN202110051916.XA CN202110051916A CN112791091B CN 112791091 B CN112791091 B CN 112791091B CN 202110051916 A CN202110051916 A CN 202110051916A CN 112791091 B CN112791091 B CN 112791091B
- Authority
- CN
- China
- Prior art keywords
- intestinal
- barrier function
- flavonoid glycoside
- use according
- cowherb seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000178320 Vaccaria pyramidata Species 0.000 title claims abstract description 25
- 235000010587 Vaccaria pyramidata Nutrition 0.000 title claims abstract description 24
- 150000007955 flavonoid glycosides Chemical class 0.000 title claims abstract description 24
- 229930182486 flavonoid glycoside Natural products 0.000 title claims abstract description 21
- 230000007358 intestinal barrier function Effects 0.000 title abstract description 13
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 230000000968 intestinal effect Effects 0.000 claims abstract description 18
- 239000002158 endotoxin Substances 0.000 claims abstract description 13
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000002966 serum Anatomy 0.000 claims abstract description 10
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 10
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims abstract description 6
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 claims abstract description 6
- 230000004888 barrier function Effects 0.000 claims abstract description 6
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 6
- 241000605059 Bacteroidetes Species 0.000 claims abstract description 5
- 241000192125 Firmicutes Species 0.000 claims abstract description 5
- 241000192142 Proteobacteria Species 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004162 Claudin-1 Human genes 0.000 claims description 9
- 108090000600 Claudin-1 Proteins 0.000 claims description 9
- 108090000304 Occludin Proteins 0.000 claims description 9
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 9
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 102000003940 Occludin Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 210000003608 fece Anatomy 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 229940069428 antacid Drugs 0.000 claims description 2
- 239000003159 antacid agent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 230000008944 intestinal immunity Effects 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000273 veterinary drug Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 102000002029 Claudin Human genes 0.000 abstract description 2
- 108050009302 Claudin Proteins 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 239000005445 natural material Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000002550 fecal effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000702460 Akkermansia Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001530119 Vaccaria Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000004877 Vaccaria hispanica subsp hispanica Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了王不留行黄酮苷在改善肠道屏障功能中的应用，属于药物开发技术领域。本发明将王不留行种子的主要活性成分——王不留行黄酮苷，应用于改善肠道屏障功能中。这种天然的物质能够显著改善动物肠道屏障功能，能使屏障功能发生损害的小鼠血清内毒素含量降低、提升肠道碱性磷酸酶水平和紧密连接蛋白表达量、粪便中的短链脂肪酸丙酸和丁酸含量，并能调节肠道菌群平衡，降低厚壁菌门的相对丰度，提高拟杆菌门和变形菌门的相对丰度。
Description
技术领域
本发明涉及王不留行黄酮苷在改善肠道屏障功能中的应用，属于药物开发技术领域。
背景技术
肠道屏障功能主要包括机械屏障、生态屏障和免疫屏障，具体主要包括肠道菌群、黏液层、肠道上皮细胞和细胞间连接以及肠道免疫系统。当肠道屏障被破坏后，进入血液循环的细菌代谢物如内毒素释放增加，肠道通透性增加，导致全身炎症反应，进一步促进慢性疾病的发生发展。
目前比较常用的改善肠道屏障功能的方法有益生菌疗法和药物疗法，益生菌疗法包括移植粪菌或微生态制剂，能与宿主和原驻菌群进行复杂的互作反应，维护微生态系统的平衡，保护机体的正常功能。但是益生菌治疗也存在不足症(产气，腹胀，便秘和头痛等)以及免疫系统低下，静脉插管或急性胰腺炎患者不宜服用益生菌的情况，安全性评估依旧缺乏。目前采取了一些天然的药物治疗方法，但是很多药物的作用效果不好，但是天然药物因为其温和型和安全性，受到越来越多的关注。
发明内容
针对目前在治疗肠道屏障功能中存在的作用效果不好、缺少效果较好天然物质，本发明提出了将王不留行种子的主要活性成分——王不留行黄酮苷，应用于改善肠道屏障功能中。
本发明提供了王不留行黄酮苷在制备预防、缓解或改善肠道屏障的产品方面的应用。
在一种实施方式中，所述产品用于提高机体肠道免疫力，调节肠道物质平衡。
在一种实施方式中，所述产品包括药物或药物组合物，所述药物或药物组合物用于(a)～(e)至少一方面：
(a)增加肠道碱性磷酸酶；
(b)提高肠道紧密连接蛋白表达量；
(c)降低血清内毒素水平；
(d)提高粪便中的短链脂肪酸水平；
(e)调节肠道菌群平衡。
在一种实施方式中，所述肠道紧密连接蛋白包括ZO-1、Claudin-1、Occludin，表达量包括转录和蛋白水平的表达量。
在一种实施方式中，所述短链脂肪酸为丙酸和丁酸。
在一种实施方式中，所述调节肠道菌群平衡为降低厚壁菌门的相对丰度，提高拟杆菌门和变形菌门的相对丰度。
在一种实施方式中，所述药物或药物组合物还包括药学上可接受的赋型剂；所述药学上可接受的赋型剂是指任何可用于药学领域的稀释剂、辅助剂和/或载体。
在一种实施方式中，所述产品包括但不限于兽药或者饲料添加剂。
在一种实施方式中，所述兽药或者饲料添加剂中还含有常规辅料。
在一种实施方式中，所述常规辅料包括填充剂、矫味剂、粘合剂、崩解剂、润滑剂、抗酸剂、以及营养强化剂中的一种或多种。
本发明的有益效果：
本发明发现王不留行黄酮苷具有改善肠道屏障功能障碍的作用：用C57BL/6小鼠制作2型糖尿病小鼠模型并将小鼠分为为空白组、模型组、王不留行黄酮苷腹腔注射组。与模型组相比，王不留行黄酮苷组血清内毒素含量显著降低，降低至正常水平；肠道碱性磷酸酶水平和紧密连接蛋白表达量升高，粪便中的短链脂肪酸丙酸和丁酸含量显著提升，趋向于正常水平。王不留行黄酮苷降低了厚壁菌门的相对丰度，增高了拟杆菌门和变形菌门的相对丰度。在属水平上，王不留行黄酮苷增加了拟杆菌属，脱硫弧菌属，阿克曼氏菌Akkermansia和Muribaculaceae的相对丰度。
附图说明
图1为各组小鼠血清内毒素水平图；
图2为各组小鼠肠道碱性磷酸酶水平图；
图3为ZO-1、Occludin，Claudin-1的基因表达水平图；
图4为ZO-1、Occludin，Claudin-1的蛋白表达水平图；
图5为小鼠粪便中短链脂肪酸含量(乙酸、丙酸、丁酸)图；
图6为小鼠肠道菌群组成的变化图。
具体实施方式
实施例中所用小鼠：C57BL/6小鼠，购自南京大学模式生物研究所。
碱性磷酸酶试剂盒：购自南京建成生物工程研究所。
实施例1：小鼠模型的制备与给药
将小鼠随机分为3组(n＝8)，分别为对照组、模型组、王不留行黄酮苷组。正常组喂普通饲料(14.7％J，13％脂肪)，其余各组饲喂HFD(21.8％J，60％脂肪，D12492)，自由进食。饮食干预8周后，除正常组外，其余两组禁食12h后均给予120mg/kg STZ(10mM柠檬酸缓冲液，pH 4.0溶解)。正常组小鼠以相同的频率给予注射缓冲液。各组继续维持当前饮食，一周后从尾静脉采血测定血糖水平。当空腹血糖(FBG)水平高于11.1mmol/L时，将小鼠作为T2DM模型。
各组继续维持当前饮食，8周后，将模型组每天腹腔注射0.1mL体积的生理盐水，王不留行黄酮苷组按1mg/kg浓度腹腔注射0.1mL。记录小鼠体重、血糖、生活状态等基本情况，共给药6周。
实施例2：王不留行黄酮苷在改善小鼠肠道屏障功能中的应用
6周后，将小鼠取出，注射10％的水合氯醛麻醉后眼球取血并处死取小鼠回肠组织和粪便。
(1)小鼠血清中内毒素的变化情况
小鼠全血低温12000rpm离心后取上清，用内毒素测定试剂盒定量几组小鼠血清中内毒素的表达，如图1和表1所示，模型组的小鼠回肠中的血清内毒素的含量显著提升，但是用王不留行黄酮苷给药后，能使得血清内毒素的含量降低至正常水平。
(2)小鼠回肠组织内碱性磷酸酶(IAP)的变化情况
用碱性磷酸酶试剂盒定量几组小鼠回肠组织内碱性磷酸酶(IAP)的表达，王不留行黄酮苷治疗后恢复了模型组碱性磷酸酶的水平，如图2和表1所示，模型组肠道中的碱性磷酸酶含量显著降低，但使用王不留行黄酮苷给药后，能够使得肠道内碱性磷酸酶含量得到提升。
表1各组小鼠血清内毒素(LPS)含量和肠道碱性磷酸酶含量
(3)ZO-1、Claudin-1、Occludin的表达水平
①ZO-1、Claudin-1、Occludin的基因表达水平
使用Trizol试剂提取回肠组织总RNA，取1ug总RNA合成cDNA。用SYBR Green进行荧光定量PCR(qPCR)，定量表达mRNA。采用2-CT法计算相对基因表达量，以β-actin为参照归一化。结果如图3和表2所示：模型组小鼠肠道组织紧密连接蛋白在转录水平都显著降低，但使用王不留行黄酮苷给药后，能够使得肠道组织紧密连接蛋白在转录水平都显著得到提升。
定量引物：
β-actin-F：AGCTGAGAGGGAAATCGTGC(SEQ ID NO.1)，
β-actin-R：TCCAGGGAGGAAGAGGATGC(SEQ ID NO.2)，
ZO-1-F：CCCACAAGGAGCCATTCCTG(SEQ ID NO.3)，
ZO-1-R：GTCAGGAGTCATGGACGCAC(SEQ ID NO.4)，
Claudin-1-F：AAAGCACCGGGCAGATACAG(SEQ ID NO.5)，
Claudin-1-R：ATCTTCCAGGCACCTCATGC(SEQ ID NO.6)，
Occludin-F：TTCGCTTATCTTGGGAGCCTG(SEQ ID NO.7)，
Occludin-R：ACATGCATCTCTCCGCCATAC(SEQ ID NO.8)。
表2各组小鼠肠道组织紧密连接蛋白的mRNA转录水平
②ZO-1、Claudin-1、Occludin的蛋白表达水平
取回肠组织样品，冰上解冻后粗略称取约30mg，置入冰上预冷的组织匀浆器中，迅速加入300ul预冷含蛋白酶/磷酸酶抑制剂的RIPA溶液，于冰上匀浆。充分匀浆裂解后，转移样品至离心管中以4℃、14000rpm离心10min，然后取上清以BCA法参照试剂盒操作说明对蛋白浓度进行检测，调整各组蛋白浓度至等同后，向样品中加入相应体积的上样缓冲液，混匀后水浴煮沸5min，-20℃冻存。蛋白质提取液经聚丙烯酰胺凝胶电泳(PAGE)分析后转移到PVDF膜上。用一抗(Occludin(Abcam，1:50000),Claudin-1(Abcam，1:2000)and ZO-1(ABclonal，1:500).β-actin(Abcam，1:1000))在4℃孵育过夜后，用辣根过氧化物酶标记的二抗(除β-actin用山羊抗鼠外，其余均用山羊抗兔，稀释比为1:2000)孵育膜。用增强型化学发光检测试剂对信号进行可视化。免疫反应条带的密度测定用Image-J软件进行分析，并归一化为β-actin的量。所有样品采用技术重复运行，实验重复3次。
结果如图4和表3所示，模型组小鼠肠道组织紧密连接蛋白的蛋白质表达水平显著降低，与模型组相比，王不留行黄酮苷可以增加了模型组小鼠ZO-1、Claudin-1、Occludin的表达。
表3各组小鼠肠道组织紧密连接蛋白的蛋白质表达水平(目标蛋白/内参)
(4)小鼠粪便短链脂肪酸变化情况
通过高效液相色谱法测定小鼠粪便短链脂肪酸浓度。取0.3g粪便样品，加入1ml去离子水，1200转/分钟离心10分钟，收集上清，加入100ul浓盐酸，混匀后加入5ml乙醚，充分混匀，常温下萃取20分钟，3500转/分钟离心10分钟，上层有机相转移到另一个管中，加入500ul 1M NaOH，充分混匀，常温下萃取20分钟，3500转/分钟离心10分钟，收集下层水相，加入100ul浓HCL混匀后过滤，通过自动进样器吸取20ul进入高效液相色谱。流动相为0.025％磷酸溶液和乙腈溶液的混合溶液，0.025％磷酸溶液:乙腈溶液＝5％:95％。乙腈在45分钟内以梯度从5％增加到95％，流速1mL/min，柱温30℃，检测波长210nm。
结果如图5和表4所示，与模型组相比，王不留行黄酮苷可显著增加粪便中丙酸和丁酸的含量。
表4各组小鼠肠道短链脂肪酸含量(mmol/g)
(5)粪便微生物群落结构的变化情况
为了评估粪便微生物群落结构，采用高通量测序方法Illumina测序，以16S rRNA基因为靶点。
每组随机抽取3只小鼠，使用DNA提取试剂盒提取样本DNA，检测DNA浓度后进行PCR扩增和文库构建，以20-30ng DNA为模板，使用上游和下游引物扩增V3和V4区域；再使用Illumina MiSeq/NovaSeq(Illumina,San Diego,CA,USA)进行测序。
上游引物：CCTACGGRRBGCASCAGKVRVGAAT(SEQ ID NO.9)；
下游引物：GGACTACNVGGGTWTCTAATCC(SEQ ID NO.10)。
如图6和表5所示，结果表明王不留行黄酮苷干预并未改变模型组小鼠的粪便微生物多样性，但在门水平上，降低了厚壁菌门(Firmicutes)的相对丰度，增高了拟杆菌门(Bacteroidetes)和变形菌门(Proteobacteria)的相对丰度。
在属水平上，王不留行黄酮苷增加了拟杆菌属Bacteroides，脱硫弧菌属Desulfovibrio，阿克曼氏菌Akkermansia和Muribaculaceae_的相对丰度。
表5各组小鼠粪便微生物状况(％)
虽然本发明已以较佳实施例公开如上，但其并非用以限定本发明，任何熟悉此技术的人，在不脱离本发明的精神和范围内，都可做各种的改动与修饰，因此本发明的保护范围应该以权利要求书所界定的为准。
SEQUENCE LISTING
<110> 江南大学
<120> 王不留行黄酮苷在改善肠道屏障功能中的应用
<130> BAA201364A
<160> 10
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> DNA
<213> 人工序列
<400> 1
agctgagagg gaaatcgtgc 20
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<400> 2
tccagggagg aagaggatgc 20
<210> 3
<211> 20
<212> DNA
<213> 人工序列
<400> 3
cccacaagga gccattcctg 20
<210> 4
<211> 20
<212> DNA
<213> 人工序列
<400> 4
gtcaggagtc atggacgcac 20
<210> 5
<211> 20
<212> DNA
<213> 人工序列
<400> 5
aaagcaccgg gcagatacag 20
<210> 6
<211> 20
<212> DNA
<213> 人工序列
<400> 6
atcttccagg cacctcatgc 20
<210> 7
<211> 21
<212> DNA
<213> 人工序列
<400> 7
ttcgcttatc ttgggagcct g 21
<210> 8
<211> 21
<212> DNA
<213> 人工序列
<400> 8
acatgcatct ctccgccata c 21
<210> 9
<211> 25
<212> DNA
<213> 人工序列
<400> 9
cctacggrrb gcascagkvr vgaat 25
<210> 10
<211> 22
<212> DNA
<213> 人工序列
<220>
<221> misc_feature
<222> (8)..(8)
<223> n is a, c, g, or t
<400> 10
ggactacnvg ggtwtctaat cc 22
Claims (10)
1.王不留行黄酮苷在制备改善肠道屏障功能的产品方面的应用，其特征在于，所述产品用于(a)～(e)至少一方面：
(a)增加肠道碱性磷酸酶；
(b)提高肠道紧密连接蛋白表达量；
(c)降低血清内毒素水平；
(d)提高粪便中的短链脂肪酸水平；
(e)调节肠道菌群平衡。
2.根据权利要求1所述的应用，其特征在于，所述产品用于提高机体肠道免疫力，调节肠道物质平衡。
3.根据权利要求2所述的应用，其特征在于，所述产品为药物。
4.根据权利要求3所述的应用，其特征在于，所述肠道紧密连接蛋白包括ZO-1、Claudin-1、Occludin，表达量包括转录和蛋白水平的表达量。
5.根据权利要求4所述的应用，其特征在于，所述短链脂肪酸为丙酸和丁酸。
6.根据权利要求5所述的应用，其特征在于，所述调节肠道菌群平衡为降低厚壁菌门的相对丰度，提高拟杆菌门和变形菌门的相对丰度。
7.根据权利要求6所述的应用，其特征在于，所述药物还包括药学上可接受的赋型剂；所述药学上可接受的赋型剂是指任何可用于药学领域的稀释剂、辅助剂和/或载体。
8.根据权利要求1所述的应用，其特征在于，所述产品为兽药或者饲料添加剂。
9.根据权利要求8所述的应用，其特征在于，所述兽药或者饲料添加剂中还含有常规辅料。
10.根据权利要求9所述的应用，其特征在于，所述常规辅料包括填充剂、矫味剂、粘合剂、崩解剂、润滑剂、以及抗酸剂中的一种或多种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110051916.XA CN112791091B (zh) | 2021-01-15 | 2021-01-15 | 王不留行黄酮苷在改善肠道屏障功能中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110051916.XA CN112791091B (zh) | 2021-01-15 | 2021-01-15 | 王不留行黄酮苷在改善肠道屏障功能中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112791091A CN112791091A (zh) | 2021-05-14 |
| CN112791091B true CN112791091B (zh) | 2022-04-29 |
Family
ID=75811017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110051916.XA Active CN112791091B (zh) | 2021-01-15 | 2021-01-15 | 王不留行黄酮苷在改善肠道屏障功能中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112791091B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948619A (zh) * | 2014-05-12 | 2014-07-30 | 江南大学 | 一种具有抗氧化抗高糖损伤的王不留行黄酮苷的应用 |
| CN106668053A (zh) * | 2017-03-03 | 2017-05-17 | 江南大学 | 王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 |
| WO2019131759A1 (ja) * | 2017-12-27 | 2019-07-04 | サントリーホールディングス株式会社 | 腸管バリア機能改善用組成物 |
-
2021
- 2021-01-15 CN CN202110051916.XA patent/CN112791091B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948619A (zh) * | 2014-05-12 | 2014-07-30 | 江南大学 | 一种具有抗氧化抗高糖损伤的王不留行黄酮苷的应用 |
| CN106668053A (zh) * | 2017-03-03 | 2017-05-17 | 江南大学 | 王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 |
| WO2019131759A1 (ja) * | 2017-12-27 | 2019-07-04 | サントリーホールディングス株式会社 | 腸管バリア機能改善用組成物 |
Non-Patent Citations (2)
| Title |
|---|
| Vaccarin protects human microvascular endothelial cells from apoptosis via attenuation of HDAC1 and oxidative stress;Xuexue Zhu等;《European Journal of Pharmacology》;20171108;第818卷;371-380 * |
| 黄酮类天然产物调控肠道微生物改善炎症性肠病;李明等;《河南工业大学学报( 自然科学版)》;20200630;第41卷(第3期);118-129 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112791091A (zh) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Le Gall et al. | Comparative effect of orally administered sodium butyrate before or after weaning on growth and several indices of gastrointestinal biology of piglets | |
| Zhang et al. | Evaluation of the efficacy of chlorogenic acid in reducing small intestine injury, oxidative stress, and inflammation in chickens challenged with Clostridium perfringens type A | |
| CN114717147B (zh) | 一种鼠李糖乳杆菌制备的缓解脂肪肝与肥胖的后生元及其应用 | |
| CN114717146B (zh) | 一种副干酪乳杆菌制备的缓解脂肪肝与肥胖的后生元及其应用 | |
| CN111686133A (zh) | 杜氏杆菌在预防和改善肥胖及其相关疾病中的应用 | |
| CN117070389A (zh) | 用于改善肠屏障功能的屎肠球菌菌株及其应用 | |
| CN115505551B (zh) | 瑞士乳杆菌及其在预防或治疗肾炎中的应用 | |
| Wang et al. | Methamphetamine induces intestinal injury by altering gut microbiota and promoting inflammation in mice | |
| Zhu et al. | Stachyose inhibits vancomycin-resistant Enterococcus colonization and affects gut microbiota in mice | |
| CN112791091B (zh) | 王不留行黄酮苷在改善肠道屏障功能中的应用 | |
| Zhong et al. | Sodium butyrate promotes gastrointestinal development of preweaning bull calves via inhibiting inflammation, balancing nutrient metabolism, and optimizing microbial community functions | |
| CN115501259B (zh) | 一种用于缓解溃疡性结肠炎的组合物和应用 | |
| Fligor et al. | A Medium-Chain Fatty Acid Analogue Prevents Intestinal Failure–Associated Liver Disease in Preterm Yorkshire Piglets | |
| TW201808314A (zh) | 改善困難梭狀桿菌感染症狀的發酵乳酸桿菌ｇｍｎｌ－２９６組合物及方法 | |
| Liu et al. | Lactobacillus rhamnosus GR-1 alleviates Escherichia coli-induced inflammation via NF-κB and MAPKs signaling in bovine endometrial epithelial cells | |
| Zhang et al. | Effect of benzoic acid, Enterococcus faecium, and essential oil complex on intestinal microbiota of laying hens under coccidia and Clostridium perfringens challenge | |
| TW201914596A (zh) | 腸道益生菌用於製備抑制大腸直腸癌細胞遷移的醫藥組合物的用途 | |
| CN113827610A (zh) | 一种肠道菌群调节剂及应用 | |
| CN108853085A (zh) | 儿茶素类和表儿茶素类化合物用于上调MicroRNA-126表达水平的用途 | |
| CN116785277B (zh) | 染料木黄酮在制备调控肠道菌丰度的制剂中的应用 | |
| CN115252638B (zh) | 一种改善肠道炎症的藜麦膳食纤维制备方法及应用 | |
| Luo et al. | Synbiotics improves growth performance and nutrient digestibility, inhibits PEDV infection and prevents intestinal barrier dysfunction by mediating innate antivirus immune response in weaned piglets challenged with PEDV | |
| CN116019839A (zh) | 乳酸肠球菌jdm1在制备预防或治疗炎症性肠病的药物中的应用 | |
| WO2023208223A1 (zh) | 药物组合物、巨球型菌及其应用 | |
| Cangiano et al. | Prophylactic feeding of neomycin to Holstein calves alters gut microbiota, bile acid metabolism, and expression of genes involved in immunometabolic regulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |